JC Polyomavirus Abundance and Distribution in Progressive Multifocal Leukoencephalopathy (PML) Brain Tissue Implicates Myelin Sheath in Intracerebral Dissemination of Infection
Over half of adults are seropositive for JC polyomavirus (JCV), but rare individuals develop progressive multifocal leukoencephalopathy (PML), a demyelinating JCV infection of the central nervous system. Previously, PML was primarily seen in immunosuppressed patients with AIDS or certain cancers, bu...
Saved in:
Published in | PloS one Vol. 11; no. 5; p. e0155897 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
18.05.2016
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Over half of adults are seropositive for JC polyomavirus (JCV), but rare individuals develop progressive multifocal leukoencephalopathy (PML), a demyelinating JCV infection of the central nervous system. Previously, PML was primarily seen in immunosuppressed patients with AIDS or certain cancers, but it has recently emerged as a drug safety issue through its association with diverse immunomodulatory therapies. To better understand the relationship between the JCV life cycle and PML pathology, we studied autopsy brain tissue from a 70-year-old psoriasis patient on the integrin alpha-L inhibitor efalizumab following a ~2 month clinical course of PML. Sequence analysis of lesional brain tissue identified PML-associated viral mutations in regulatory (non-coding control region) DNA, capsid protein VP1, and the regulatory agnoprotein, as well as 9 novel mutations in capsid protein VP2, indicating rampant viral evolution. Nine samples, including three gross PML lesions and normal-appearing adjacent tissues, were characterized by histopathology and subject to quantitative genomic, proteomic, and molecular localization analyses. We observed a striking correlation between the spatial extent of demyelination, axonal destruction, and dispersion of JCV along white matter myelin sheath. Our observations in this case, as well as in a case of PML-like disease in an immunocompromised rhesus macaque, suggest that long-range spread of polyomavirus and axonal destruction in PML might involve extracellular association between virus and the white matter myelin sheath. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Current address: JadeBio, San Diego, CA, United States of America Competing Interests: KAW and KGM are employees of Novartis. SMS reports no conflicts. RJF has received personal consulting fees from Actelion, Biogen, Genentech, Mallinckrodt, MedDay, Novartis, Teva, and XenoPort; has served on advisory committees for Biogen and Novartis; and has received research grant funding from Novartis. KAW, MT, JW, AB, CER, GS, CQ, RWD, and SEG are former, and KD, EC-M, CS, PC, JPC, and WM are current employees of Biogen. Funding by Biogen and Cleveland Clinic does not alter adherence to PLOS ONE policies on sharing data and materials. Current address: Biomarker Development-Oncology, ImmunoGen, Waltham, MA, United States of America Current address: Abbvie, Worcester, MA, United States of America Current address: Preclinical Safety, Novartis Institutes for BioMedical Research, Cambridge, MA, United States of America Current address: Independent Consultant, Portland, OR, United States of America Conceived and designed the experiments: SEG KAW CQ MT EC-M JW AB CER CS PC GS JPC SMS RJF WM. Performed the experiments: CQ MT KAW KD JW AB CER CS PC GS SMS. Analyzed the data: KAW KD JW AB CER CS PC GS. Contributed reagents/materials/analysis tools: RWD KGM SVW. Wrote the paper: KAW EC-M SEG. Current address: Independent Consultant, Durham, NC, United States of America Current address: Leica Biosystems, Companion Diagnostics Division, Danvers, MA, United States of America Current address: Human Metabolome Technologies America, Boston, MA, United States of America Current address: Vertex Pharmaceuticals, Boston, MA, United States of America |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0155897 |